Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd
sales@dingminpharma.com
86-311-67591193
Model No.: CAS:1420477-60-6
Brand: DM
Packaging: double PE with aluminium foil bag
Productivity: 100kg/month
Transportation: Ocean,Air
Place of Origin: Hebei,China
Supply Ability: 100kg/month
Certificate: ISO9001
Port: Shanghai,Beijing,Shenzhen
Payment Type: L/C,T/T
Incoterm: FOB,CIF
CAS:1420477-60-6
Appearance:White crystalline powder
Application: API
Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.
Product Categories : APIs And Intermediates > Acalabrutinib
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Contact Now